### ORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



# INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7: A61K 31/35, 9/50, A61P 37/00

(11) International Publication Number:

WO 00/27392

A1 (43) International Publication Date:

18 May 2000 (18.05.00)

(21) International Application Number:

PCT/GB99/03731

(22) International Filing Date:

9 November 1999 (09.11.99)

(30) Priority Data:

9824604.4

11 November 1998 (11.11.98)

(71) Applicant (for all designated States except US): HEWLETT HEALTHCARE LIMITED [GB/GB]; Yew Turn, 7 Church Lane, Lockington, Derby DE74 2TF (GB).

(72) Inventor; and

(75) Inventor/Applicant (for U\$ only): WIGMORE, Alexander, James [GB/GB]; Yew Turn, 7 Church Lane, Lockington, Derby DE74 2TF (GB).

(74) Agent: BASSETT, Richard, S.; Eric Potter Clarkson, Park View House, 58 The Ropewalk, Nottingham NGI 5DD (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published** 

With international search report.

(54) Title: CHROMONE ENTERIC RELEASE FORMULATION

(57) Abstract

Orally administered sodium cromoglycate has been found to be effective in the treatment of allergic conditions such as asthma, general food allergies, ulcerative colitis, atopic eczema, chronic urticaria and irritable bowel syndrome if it is presented such that the sodium cromoglycate becomes bioavailable within (10) minutes of exposure to intestinal fluid. The sodium cromoglycate may be presented as enteric-coated tablets or individually enteric-coated pellets or microgranules packaged with disintegrant in a ratio of at least 1.2:1 distintegrant: sodium comoglycate (w:w). Optionally, the patients are first selected to have a total serum IgE level of at least 150 iu/ml.

BEST AVAILABLE COPY

# BEST AVAILABLE COPY

## FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	12	Slovenia.
AM	Armenia	FI	Finland	LT ·	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV.	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	МC	Мопасо	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	_	Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	1:1	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	ΙΤ	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Vict Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
Cυ	Cuba	KZ	Kazakstan	RO.	Romania		
cz	Czech Republic	ic	Saint Lucia	RU	Russian Federation		
DE	Germany	ü	Liechtenstein	SD	Sudan	•	•
DK .	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore .		